Search

Your search keyword '"Tania Hernáez-Alsina"' showing total 2 results
Start Over Author "Tania Hernáez-Alsina" Publisher elsevier bv
2 results on '"Tania Hernáez-Alsina"'

1. Significant heterogeneity in the diagnosis and long-term management of Wilson disease: Results from a large multicenter Spanish study

Author

Marina Berenguer, Mercedes Vergara, Carolina Almohalla, Alicia Hernandez, Sonia Blanco, Milagros Testillano, Eva Girona, Marta Casado, Miren García, Maria-Vega Catalina, Carolina Muñoz, Maria Luisa Gutierrez, Esther Molina, Miriam Romero, Alejandra Otero, Tania Hernáez-Alsina, Vanessa Bernal-Monterde, Sara Lorente, Helena Masnou, Lucia Bonet, Susana Soto, Concha Gisbert, María-Paz Valer, Judith Gomez, Gemma Pacheco, Julia Morillas, Martha Gonzalez, Nuria Dominguez, Maria Lazaro, Sonia Pascual, Immaculada Castelló, and Rocio Gonzalez

Subjects
Hepatology, Gastroenterology
Published
2022

2. Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals

Author

Cassia Guedes-Leal, Tania Hernáez-Alsina, Maria Reig, Berta Caballol-Oliva, and Álvaro Díaz-González

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, Hepatitis C virus, Population, Disease, medicine.disease_cause, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Hepatectomy, Humans, Medicine, In patient, Prospective Studies, Risks and benefits, education, neoplasms, Retrospective Studies, education.field_of_study, business.industry, Interferon free, Liver Neoplasms, Hepatitis C, Chronic, medicine.disease, Embolization, Therapeutic, digestive system diseases, 030104 developmental biology, Hepatocellular carcinoma, Disease Progression, 030211 gastroenterology & hepatology, Interferons, Neoplasm Recurrence, Local, business
Abstract

Eradication of the hepatitis C virus (HCV) with interferon-free therapies (DAAs) has modified the course of the disease, as the rate of patients with compensated cirrhosis who achieve a sustained virological response exceeds 95%. However, the impact on development of hepatocellular carcinoma (HCC) is currently in dispute. This argument could be divided into different key points: the impact of DAA on rate of HCC recurrence, the temporal link between starting DAAs and HCC recurrence, and finally, the aggressive pattern of HCC. Therefore, the aim of this review is to analyse the available results in this population of patients from a clinical perspective where the risks and benefits of HCV eradication with DAA therapies are evaluated in patients with complete response of HCC.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results